Cannabis Bioscience International Holdings, Inc. (CBIH) has begun its Evidence Sprint 2026 program, a year‑long effort to generate robust clinical data for cannabinoid therapies. The company’s leadership announced the launch on January 12, 2026, and simultaneously filed a formal coordination request with the Centers for Medicare & Medicaid Services (CMS). The request has been placed in CMS’s institutional coordination channel, and CBIH expects an update as the process moves forward.
The program is designed to accelerate the development of protocols, operational collaborations, and projects that can secure competitive funding. By leveraging its Alpha Research Institute and Pharmacology University, CBIH aims to produce data that meets institutional review standards and can support future clinical trials and educational initiatives. The initiative is a direct response to the federal momentum toward rescheduling cannabis to Schedule III, following a December 18, 2025 executive order that directed the Attorney General to expedite the rescheduling process.
CBIH’s R&D Director, Dr. Rosangel Andrades, emphasized that policy momentum alone is insufficient; execution will determine the real impact. “The Schedule III transition is a once‑in‑a‑generation inflection point, but the true benefit will come from building standards, research infrastructure, and translating science into compliant clinical pathways,” he said. Chief Patent Officer Jennifer Salguero added, “CBIH is in execution mode: institutions, grants, and evidence.” These statements underscore the company’s focus on turning scientific research into actionable medical evidence and securing a credible position in the emerging medical cannabis market.
The federal rescheduling effort is a tailwind that could open Medicare coverage for hemp‑derived CBD products and expand the addressable market for cannabinoid therapies. CMS’s formal acknowledgment of CBIH’s coordination request signals a willingness to engage with companies that can provide high‑quality evidence. If successful, the program could position CBIH as a key partner for future research funding and potentially create new revenue streams through clinical trial contracts and educational services.
While the announcement does not include financial results, the strategic initiative signals confidence in the company’s intellectual property portfolio—10 patent applications filed and 12 more ready for submission—and its research capabilities. By aligning its program with federal policy changes, CBIH is aiming to accelerate its path to market approval and establish itself as a credible, evidence‑driven player in the medical cannabis sector.
The launch of Evidence Sprint 2026 and the formal CMS coordination request represent a significant step for CBIH, aligning its research agenda with a favorable regulatory environment and positioning the company to capitalize on emerging opportunities in medical cannabis research and potential Medicare coverage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.